OBJECTIVES: The objective of this study is to assess the health care costs associated with Disease Modifying Therapies (DMTs) for patients diagnosed with Relapsing Remitting Multiple Sclerosis (RRMS).  METHODS: A large US administrative retrospective claims database was used to identify patients diagnosed with RRMS and were prescribed DMTs between January 2010 to December 2012 were included in the study. All patients were ≥ 18 years of age and continuously enrolled in the same health plan for at least a year. Descriptive statistics were performed on the data where appropriate.  RESULTS: There were a total of 741,065 patients that met the study inclusion criteria. Patients on average were charged $4161.40 ± 2817.59 for their DMTs treatment during the study period. However, the allowed amount by the health plan was $3681.33 ± 1847.82 and the actual paid amount was $3580.63 ± 1859.14. On average, patient’s deductible was $21.72 ± 228.50 and patient co-payment was $82.94 ± 285.47. For patients whose prescription was on their health plans formulary paid on average higher costs compared to patients who were not (paid amount $3595 vs $3370; allowed amount $3686 vs 3493). Even though most of the patients were females, but they had overall lower costs compared to males (amount allowed $3677 vs $3689; paid amount $3576 vs $3590; deductible $21 vs $23; co-payment $82 vs $84). Patients who received treatment in the Midwest region of the USA had a higher costs compared to east, south, and west regions (paid amount $3672 vs $3596 vs $3468 vs $3461).  CONCLUSIONS: The mean cost of treatment with any DMTs for the treatment of RRMS patients is $4161. The drug formulary status did not play a role in determining overall healthcare costs. Females and patients from Midwest region generally had higher costs.